Wave Life Sciences Ltd. - WVE STOCK NEWS

IMPACT

SENTIMENT

03/02/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

IMPACT

SENTIMENT

02/09/2023 04:05 PM

WVE : Nasdaq

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

IMPACT

SENTIMENT

12/19/2022 07:37 AM

WVE : Nasdaq

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

IMPACT

SENTIMENT

12/13/2022 07:30 AM

WVE : Nasdaq

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

IMPACT

SENTIMENT

11/10/2022 07:30 AM

WVE : Nasdaq

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

IMPACT

SENTIMENT

11/09/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

IMPACT

SENTIMENT

11/03/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

IMPACT

SENTIMENT

10/03/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

IMPACT

SENTIMENT

09/28/2022 01:30 PM

WVE : Nasdaq

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

IMPACT

SENTIMENT

09/27/2022 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#3558 Ranked by Market Cap

N/A Ranked by Dividends

WVE Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country Singapore

City 7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.